Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACXPNASDAQ:CDTNASDAQ:HCWBNASDAQ:SLXN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACXPAcurx Pharmaceuticals$0.31-7.6%$0.37$0.30▼$3.33$7.16M-1.38176,284 shs375,529 shsCDTConduit Pharmaceuticals$2.33-5.7%$6.72$2.31▼$4,680.00$1.86M2.02150,454 shs203,697 shsHCWBHCW Biologics$5.45-0.9%$7.66$5.00▼$100.80$7.84M0.83453,866 shs36,835 shsSLXNSilexion Therapeutics$0.87-1.2%$0.91$0.58▼$41.85$7.60M0.124.94 million shs137,309 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACXPAcurx Pharmaceuticals-5.69%-5.01%-13.11%-28.39%-86.74%CDTConduit Pharmaceuticals-2.37%-8.52%-58.48%-84.89%-99.92%HCWBHCW Biologics+5.36%-7.56%-45.27%-59.56%-87.50%SLXNSilexion Therapeutics-2.87%-3.90%-8.72%-32.40%+88,559,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACXPAcurx Pharmaceuticals3.2402 of 5 stars3.55.00.00.02.61.70.6CDTConduit Pharmaceuticals0.1864 of 5 stars0.02.00.00.02.70.00.0HCWBHCW Biologics3.4341 of 5 stars3.55.00.00.02.83.30.0SLXNSilexion TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACXPAcurx Pharmaceuticals 3.00Buy$8.002,522.95% UpsideCDTConduit Pharmaceuticals 4.00Strong BuyN/AN/AHCWBHCW Biologics 3.00Buy$35.00542.20% UpsideSLXNSilexion Therapeutics 3.00Buy$5.00471.69% UpsideCurrent Analyst Ratings BreakdownLatest CDT, ACXP, SLXN, and HCWB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025HCWBHCW BiologicsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$120.00 ➝ $35.005/15/2025ACXPAcurx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$8.003/20/2025SLXNSilexion TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$9.00 ➝ $5.003/19/2025ACXPAcurx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACXPAcurx PharmaceuticalsN/AN/AN/AN/A$0.34 per shareN/ACDTConduit PharmaceuticalsN/AN/AN/AN/A($0.62) per shareN/AHCWBHCW Biologics$1.45M5.43N/AN/A$0.37 per share14.73SLXNSilexion TherapeuticsN/AN/A$0.60 per share1.46($6.63) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACXPAcurx Pharmaceuticals-$14.58M-$0.70N/AN/AN/AN/A-392.36%-223.78%8/8/2025 (Estimated)CDTConduit Pharmaceuticals-$540K-$534.48N/A∞N/AN/AN/A-328.67%N/AHCWBHCW Biologics-$24.99M-$23.25N/A∞N/A-1,067.82%-2,516.84%-132.95%N/ASLXNSilexion Therapeutics$260KN/A0.00∞N/AN/AN/A-249.43%6/17/2025 (Estimated)Latest CDT, ACXP, SLXN, and HCWB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025CDTConduit PharmaceuticalsN/A-$19.80N/A-$1.32N/AN/A5/15/2025Q1 2025HCWBHCW BiologicsN/A-$0.05N/A-$0.05N/AN/A5/13/2025N/ASLXNSilexion TherapeuticsN/A-$0.26N/A-$0.26N/AN/A5/12/2025Q1 2025ACXPAcurx Pharmaceuticals-$0.14-$0.11+$0.03-$0.11N/AN/A3/28/2025Q4 2024CDTConduit PharmaceuticalsN/A-$304.95N/A-$20.33N/AN/A3/28/2025Q4 2024HCWBHCW BiologicsN/A-$3.20N/A-$0.08N/A$0.40 million3/17/2025Q4 2024ACXPAcurx Pharmaceuticals-$0.18-$0.16+$0.02-$0.16N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACXPAcurx PharmaceuticalsN/AN/AN/AN/AN/ACDTConduit PharmaceuticalsN/AN/AN/AN/AN/AHCWBHCW BiologicsN/AN/AN/AN/AN/ASLXNSilexion TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACXPAcurx PharmaceuticalsN/A1.801.80CDTConduit PharmaceuticalsN/A0.120.12HCWBHCW BiologicsN/A0.070.07SLXNSilexion TherapeuticsN/A0.850.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACXPAcurx Pharmaceuticals11.53%CDTConduit Pharmaceuticals3.29%HCWBHCW Biologics2.96%SLXNSilexion Therapeutics10.95%Insider OwnershipCompanyInsider OwnershipACXPAcurx Pharmaceuticals26.00%CDTConduit Pharmaceuticals4.05%HCWBHCW Biologics42.70%SLXNSilexion Therapeutics33.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACXPAcurx Pharmaceuticals323.48 million11.99 millionOptionableCDTConduit Pharmaceuticals3798,000710,000Not OptionableHCWBHCW Biologics401.44 million22.32 millionNot OptionableSLXNSilexion TherapeuticsN/A8.69 million1.07 millionN/ACDT, ACXP, SLXN, and HCWB HeadlinesRecent News About These CompaniesSilexion Therapeutics announces preclinical results on SIL204May 30, 2025 | finance.yahoo.comSilexion Therapeutics Corp (SLXN)’s RNAi Therapy Blocks 90% of Colorectal TumorsMay 30, 2025 | msn.comSilexion Therapeutics Announces Groundbreaking Preclinical Results: SIL204 Shows Strong Efficacy in Pancreatic, Colorectal, and Lung CancersMay 29, 2025 | finance.yahoo.comSilexion's SIL204 Completes Key Preclinical Studies In KRAS-Mutant CancersMay 23, 2025 | nasdaq.comSilexion Therapeutics Receives Nasdaq Delisting NoticeMay 23, 2025 | tipranks.comPESG Research Report: A Review of Silexion Therapeutics' Innovative KRAS-Driven Cancer TreatmentMay 22, 2025 | globenewswire.comSilexion Therapeutics Corporation Registered ShsMay 22, 2025 | markets.businessinsider.comSilexion Therapeutics Completes Key Preclinical Studies Exploring SIL204’s Potential Impact on Colorectal and Lung CancerMay 21, 2025 | finance.yahoo.comSilexion Therapeutics Completes Preclinical Study on SIL204 for Expanded KRAS-Driven Cancer TherapiesMay 21, 2025 | quiverquant.comSilexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung CancerMay 21, 2025 | globenewswire.comSilexion Therapeutics Corp: Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 14, 2025 | finanznachrichten.deSilexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 13, 2025 | globenewswire.comSilexion Therapeutics enters collaboration with CatalentApril 25, 2025 | markets.businessinsider.comSilexion Therapeutics Enters Strategic Collaboration with Catalent to Advance SIL204 Development for KRAS-Driven CancersApril 23, 2025 | quiverquant.comSilexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing ActivitiesApril 23, 2025 | globenewswire.comSilexion Therapeutics announces expanded development plan for SIL204March 28, 2025 | markets.businessinsider.comSilexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical DataMarch 28, 2025 | globenewswire.comSilexion announces completion of expanded development plan for SIL204March 21, 2025 | markets.businessinsider.comSilexion Therapeutics price target lowered to $5 from $9 at MaximMarch 21, 2025 | markets.businessinsider.comSilexion Therapeutics Corp. Announces Expanded Development Plan for SIL204 at NeauxCancer 2025 ConferenceMarch 21, 2025 | quiverquant.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCDT, ACXP, SLXN, and HCWB Company DescriptionsAcurx Pharmaceuticals NASDAQ:ACXP$0.30 -0.03 (-7.60%) Closing price 04:00 PM EasternExtended Trading$0.32 +0.02 (+4.92%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.Conduit Pharmaceuticals NASDAQ:CDT$2.33 -0.14 (-5.67%) Closing price 04:00 PM EasternExtended Trading$2.33 0.00 (-0.21%) As of 04:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.HCW Biologics NASDAQ:HCWB$5.45 -0.05 (-0.91%) Closing price 04:00 PM EasternExtended Trading$5.52 +0.06 (+1.19%) As of 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.Silexion Therapeutics NASDAQ:SLXN$0.87 -0.01 (-1.24%) Closing price 04:00 PM EasternExtended Trading$0.88 +0.01 (+0.62%) As of 04:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
